Trial Profile

A phase I clinical trial of PBGENE-PCSK9 for Familial Hypercholesterolemia

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PBGENE-PCSK9 (Primary)
Indications Hyperlipoproteinaemia type IIa
Focus Adverse reactions
Sponsors iECURE

Most Recent Events

10 Nov 2021 According to a Precision BioSciences media release, the company expects CTA filing as early as 2022.
17 Sep 2021 New trial record
09 Sep 2021 According to a Precision BioSciences media release, the company plans to file a Clinical Trial Application as early as 2022 for PBGENE-PCSK9 for Familial Hypercholesterolemia. The company will collaborate with iECURE for phase I studies of PBGENE-PCSK9.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com